Physician profile
Christopher Ciccone
NPI 1659377356
$1,704.95
in general payments reported to CMS, 2019-2025
25 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $251 · 2021: $187 · 2022: $41.65 · 2023: $174 · 2024: $139 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $180.00 | 2019-2020 | |
| Abbvie INC. | $154.81 | 2019-2025 | Ubrelvy |
| Pfizer INC. | $147.76 | 2019-2025 | |
| Lilly USA, LLC | $146.26 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $144.59 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.05 | 2019-2021 | |
| Amgen INC. | $110.62 | 2019-2025 | Evenity |
| Insightec,INC | $106.18 | 2023 | Exablate |
| Merck Sharp & Dohme LLC | $103.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $102.77 | 2019-2020 | |
| Amarin Pharma, INC. | $56.46 | 2019-2020 | |
| Glaxosmithkline, LLC. | $52.33 | 2020 | |
| Abbott Laboratories | $44.78 | 2021-2024 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $34.82 | 2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $29.42 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $24.28 | 2019 | |
| Allergan, INC. | $21.30 | 2020 | |
| Philips North America LLC | $20.79 | 2024 | (Ck6) Holter |
| Metuchen Pharmaceuticals | $20.36 | 2019 | |
| Astellas Pharma US INC | $16.65 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.07 | 2023 | Unithroid |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2025 | Ajovy |
| Kowa Pharmaceuticals America, INC. | $13.88 | 2019 | |
| Sanofi Pasteur INC. | $12.23 | 2019 | |
| Endo Pharmaceuticals INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ciccone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.